Literature DB >> 6186814

Assessment of viral and immune factors in EMC virus-induced diabetes: effects of cyclosporin A and interferon.

B Vialettes, D Baume, C Charpin, J De Maeyer-Guignard, P Vague.   

Abstract

EMC virus-induced diabetes in mice may be a model of human type I diabetes. It is postulated that auto-immune reaction plays a role in beta cell destruction after viral aggression. The use of anti-viral (interferon) or immunosuppressive drugs (Cyclosporin A) could contribute to an understanding of the pathogenesis of diabetes in this model. Early or late administration of cyclosporin A increased mortality and frequency of diabetes in female mice and did not influence these parameters in males despite a reduction of pancreatic inflammatory lesions. Interferon administered at the time of virus inoculation diminished mortality in both sexes and frequency of diabetes in males. These results are against an autoimmune pathogenesis for diabetes in this model and suggest that the virus plays the major role in beta cell damage.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186814

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  6 in total

1.  Effect of interferon and double-stranded RNA on B-cell function in mouse islets of Langerhans.

Authors:  C J Rhodes; K W Taylor
Journal:  Biochem J       Date:  1985-05-15       Impact factor: 3.857

2.  Role of macrophages in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice.

Authors:  H S Baek; J W Yoon
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Possible role of macrophage-derived soluble mediators in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice.

Authors:  K Hirasawa; H S Jun; K Maeda; Y Kawaguchi; S Itagaki; T Mikami; H S Baek; K Doi; J W Yoon
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Remissions in newly diagnosed type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy.

Authors:  V A Koivisto; A Aro; K Cantell; M Haataja; J Huttunen; S L Karonen; P Mustajoki; R Pelkonen; P Seppälä
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Acute and chronic animal models for the evaluation of anti-diabetic agents.

Authors:  Suresh Kumar; Rajeshwar Singh; Neeru Vasudeva; Sunil Sharma
Journal:  Cardiovasc Diabetol       Date:  2012-01-19       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.